secwatch.observer — SEC 8-K summary
======================================

Issuer:     Skye Bioscience, Inc. (SKYE)
CIK:        0001516551
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0001516551-23-000027
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 1.02, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Skye Bioscience enters master transaction agreement with major shareholder to convert debt and exercise warrants
--------------------------------------------------------------------------------

- Emerald Health Sciences exercised 16,641,486 warrants for $282,905, paid by reducing Skye's debt under the Credit Agreement.
- Remaining debt of $1,597,236 converted into 41,379,164 shares of common stock at $0.0386 per share.
- Credit Agreement terminated in full after the conversion and warrant exercise.
- Emerald Health Sciences agreed to use best efforts to distribute its Skye shares to its shareholders pro-rata upon a national exchange listing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1516551/000151655123000027/0001516551-23-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1516551/000151655123000027/skye-20230216.htm
  HTML page:      https://secwatch.observer/filing/0001516551-23-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer